Search Results
The default setting for search results displays All Content. If you prefer to see recent content only, please adjust the date filter.
Filter your results:
Types
Topics
344 Results Found
AHA, Others Files Amicus Brief Against Novartis’ Motion to Block Maine’s 340B Contract Pharmacy Law
AHA, others file amicus brief opposing Novartis’ motion for preliminary injunction against enforcement of Maine’s 340B contract pharmacy law.
AHA, Others File Amicus Brief Against Abbvie’s Motion to Block Maine’s 340B Contract Pharmacy Law
AHA, others file amicus brief opposing AbbVie’s motion for preliminary injunction against enforcement of Maine’s 340B contract pharmacy law.
AHA 340B Advocacy Alliance Bulletin - September 16, 2025
AHA 340B Advocacy Alliance Bulletin - September 16, 2025.
AHA comments on CY 2026 OPPS proposed rule
The AHA commented Sept. 15 on the Centers for Medicare & Medicaid Services calendar year 2026 outpatient prospective payment system and ambulatory surgical center payment system proposed rule.
AHA Details Legislative Priorities for Congressional Leaders
Hospitals and health systems are experiencing significant financial pressures that challenge their ability to provide 24/7 care for the patients and communities they serve. As Congress begins to focus on its end-of-the-year work, America’s hospitals and health systems respectfully request that you consider the following priorities.
Appeals court upholds lower court denial of AbbVie’s preliminary injunction, preserving Mississippi 340B contract pharmacy law
The United States Court of Appeals for the Fifth Circuit Sept. 12 affirmed a Mississippi Court’s decision to deny AbbVie’s request for a preliminary injunction against enforcement of state law protecting 340B pricing for contract pharmacy arrangements.
AHA 340B Advocacy Alliance Bulletin - September 8, 2025
AHA 340B Advocacy Alliance for September 8, 2025.
AHA urges FTC, DOJ to investigate anticompetitive activity by drug companies on 340B rebate models
The AHA Sept. 8 urged the Federal Trade Commission and Antitrust Division of the Department of Justice to investigate several drug companies’ concerted efforts to impose rebate models within the 340B Drug Pricing Program, saying the actions may violate antitrust laws.
AHA Letter to FTC and DOJ Re: Anticompetitive Activity by Drug Companies with Respect to 340B “Rebate Models”
AHA letter to the Federal Trade Commission and Department of Justice regarding anticompetitive activity by drug companies with respect to 340B “rebate models.”